Patent Number: 7,101,991

Title: Compositions and methods for treatment of prostate and other cancers

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Inventors: Gleave; Martin E. (Vancouver, CA), Rocchi; Palma (Vancouver, CA), Signaevsky; Maxim (Vancouver, CA), Beraldi; Eliana (Vancouver, CA)

Assignee: The University of British Columbia

International Classification: C07H 21/04 (20060101); A61K 48/00 (20060101); C12Q 1/68 (20060101); C07H 21/02 (20060101)

Expiration Date: 9/05/02018